HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2025-03-27 (nasdaq.com)
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma |
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. resolving patent litigation related to Rigel's product Tavalisse (fostamatinib disodium hexahy
Read more
2025-02-22 (medicaldialogues.in)
Hetero Labs Gets CDSCO Panel Nod To Study Antipsychotic Drug Brexpiprazole Tablets
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to Hetero Labs for conducting a bioequivalence study (BE) of...
Read more
2025-02-21 (telanganatoday.com)
Chemical spill at Hetero pharma unit in Sangareddy injures three workers; Probe underway-
The incident happened when the empoyees were filling the reactor with chemicals. However, the management of Hetero kept the incident secret.
Read more
2025-02-13 (pmfarma.com)
Working Offers of Kam Hospitals Madrid in Madrid, Spain |
Kam Hospitals Madrid job in Spain. Know these and other job offers for the pharmaceutical sector in PMFARMA
Read more
2025-02-12 (medicaldialogues.in)
NPPA Fixes Prices of 42 Popular Drugs Including Empagliflozin & Metformin, Dapagliflozin & Glimepiride; Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 42 essential drugs, including popular brands such as Empagliflozin &...
Read more
2025-02-11 (jdsupra.com)
ANDA Litigation Settlements - Winter 2024 | Robins Kaplan LLP - JDSupra
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that...
Read more
2025-01-31 (downtoearth.org.in)
The Illusion of Access: Flawed Voluntary Licensing in the Pharma Industry
In December, there was a sense of triumph in Geneva when it was announced that Hetero Drugs of Hyderabad had received the green light from the US Food and Drug
Read more
2025-01-10 (businessupturn.com)
JSW Energy subsidiary completes acquisition of 125 MW RE Assets |
JSW Neo Energy Limited (JSW Neo), a fully-owned subsidiary of JSW Energy Limited, has successfully acquired 125 MW of renewable energy assets from Hetero Labs Limited and Hetero Drugs Limited. These assets, housed under three Special Purpose Vehicles (SPVs), are located in Andhra Pradesh and Maharashtra. The wind energy projects have long-term power purchase agreements […]
Read more
2025-01-05 (rbc.ru)
How the deal with Gilead illustrates India's transformation into a “forge of generics” - RBC Industries
India is one of the leaders in the market of generics, inexpensive alternatives to patented drugs. At the end of 2024, the country strengthened its position by concluding a deal with Gilead Sciences Ireland and planning the joint production of an “HIV vaccine”
Read more
2024-12-24 (oncodaily.com)
FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment -
FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment / Access to Oncology Medicines Coalition, cancer, chronic myeloid
Read more